Emmaus Life Sciences Announces Partnership with UpScript to Provide Telehealth Solutions to Sickle Cell Disease Patients

TORRANCE, Calif.: TORRANCE, Calif., Nov. 11, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced a partnership with UpScript IP Holdings, LLC. (UpScript), to offer telehealth solutions to sickle cell disease patients, expanding access to...

Click to view original post